TECH BUYER Mar 2023 - IDC Perspective - Doc # US50382823
Real-World Evidence, Social Determinants of Health, and Digital Biomarkers in Driving Patient Recruitment
Abstract
This IDC Perspective reviews the paradigm shift of the life sciences industry from conventional models to patient recruitment strategies that focus on using RWD, leveraging SDoH to drive diversity and equity in clinical trials, and the significant potential of digital biomarkers in driving patient recruitment. It reviews the factors that need to be taken into consideration when using RWD and the key players in this space and provides guidance to technology buyers as well.
"The use of RWD to refine eligibility criteria and optimize patient recruitment is becoming the new normal. Leveraging SDoH to drive diversity in clinical trials, and the use of digital biomarkers, especially for recruiting patients with neurological diseases, are the bellwether of a coming revolution in clinical trial recruitment strategy," says Dr. Nimita Limaye, research VP, Life Sciences R&D Strategy and Technology at IDC Health Insights.
Coverage
Subscriptions Covered
IDC Health Insights: Worldwide Life Science R&D Strategy and Technology
Companies Covered
LexisNexis Group, Wipro Limited, NVIDIA Corporation, Cognizant Technology Solutions Corporation, Atos SE, TriNetX LLC, Power CORP., Merative L.P., IQVIA Inc., Trialbee AB, Medable Inc., Clarify Health Solutions, Inc., Veradigm LLC, Medidata Solutions, Inc., THREAD Research LTD, ZS Associates Inc., Antidote Technologies, Inc., Oracle Corporation, Optum, Inc., Koneksa Health Inc., Truveta Inc., Allscripts Healthcare LLC, Komodo Health Inc., Clariness GmbH, Science 37, Inc., Infosys Limited, Verily Life Sciences LLC
Regions Covered
Topics Covered
Analytic applications, Cognitive/artificial intelligence, Recruitment, Technology buyer, Wearables
Vertical Markets
Health delivery strategies, Health treatment strategies, Knowledge-based medicine
Content
List of Figures
Get More
When you purchase this document, the purchase price can be applied to the cost of an annual subscription, giving you access to more research for your investment.